Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b double-blind, placebo-controlled, multiple-dose trial evaluated the safety and tolerability of APG808 in adult patients with mild-to-moderate asthma

Next Previous
Trial Profile

A phase 1b double-blind, placebo-controlled, multiple-dose trial evaluated the safety and tolerability of APG808 in adult patients with mild-to-moderate asthma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 808 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

  • 12 May 2025 Interim results presented in an Apogee Therapeutics media release
  • 12 May 2025 According to Apogee Therapeutics media release, company announced positive interim data from its Phase 1b trial of APG808, in patients with mild-to-moderate asthma.
  • 02 Dec 2024 According to Apogee Therapeutics media release,data expected in the first half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top